Vetted consultants
How we vet consultants
Only firms that pass our review are listed here.
- We assess regulatory experience, service scope, and professional credentials.
- Approved status may be revoked if standards are not maintained.
April 26, 2024
Approximately 5 minutes
Reviewed by Nate Lam, Founder & Director, ElendiLabs
Predicate Device Identification in China (Same-Type Devices)
In China, Predicate Device Identification, locally referred to as 'Same-Type' devices, is a critical regulatory strategy for Class II and Class III medical device manufacturers. Successfully identifying and comparing a device to an already-approved predicate can often exempt the product from costly and time-consuming local clinical trials.
🔍 The Role of Predicate Devices
The core function of identifying a predicate device is to demonstrate the applicant's product is substantially equivalent in terms of safety and efficacy to a device already legally marketed in China.
- Clinical Trial Avoidance: If equivalence can be proven, manufacturers can submit a Clinical Evaluation Report (CER) in lieu of a full clinical trial.
- Narrow Definition: The NMPA maintains a very narrow definition of a "Same-Type Device." Products must share similar technology, the same indications for use, and sometimes even the same raw materials (e.g., a drug-eluting stent must use the same drug in similar quantities as its predicate).
📝 The Clinical Evaluation Report (CER)
The CER is the required document used to support a "Same-Type" device claim. It must include:
- Thorough Comparison: A detailed comparison of the applicant device against the identified predicate device(s) across critical performance, structural, and intended use parameters.
- Clinical Evidence: A summary of clinical and non-clinical data, coupled with a systematic literature review, to prove that the device is safe and effective in the intended clinical setting.
❓ Clarifying NMPA Expectations
Historically, manufacturers faced uncertainty regarding whether their product would be considered "Same-Type" until the formal review began. To improve transparency, the NMPA established a mechanism for pre-submission inquiries:
- Formal Inquiry Process: Manufacturers can seek feedback from the NMPA on the specific performance parameters and data the agency will expect for a Same-Type Device application. This process is designed to reduce the previous turnaround time from approximately six months to about two months, providing essential clarity for regulatory planning.
📜 Clinical Trial Exemption List
While the predicate pathway is a key alternative, the NMPA also maintains an Exemption List for certain product types whose technology is considered mature and has a proven history of safety. Products on this list are automatically exempt from clinical trials but still require the submission of a CER.
Need Regulatory Help? Try Our Platform
Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.
Registered Pharmacist · AI Engineer · Director, ElendiLabs
Registered pharmacist, AI engineer, HKHAIS founder, and pharmaceutical & medical device SEO/GEO specialist.
Ask Anything
We'll follow up with you personally.
100% response rate • Reply within 7 business days
Related Articles
Approximately 5 minutes
China NMPA Medical Device Registration Guide
Learn China NMPA medical device registration requirements, including classification, legal agent duties, local testing, clinical evidence, and MDRC approval.
Approximately 5 minutes
China NMPA IVD Registration: Testing and Clinical Data
Understand China NMPA IVD registration, including classification, local type testing, clinical data requirements, legal agent duties, and MDRC approval.
Approximately 5 minutes
NMPA Clinical Requirements: Clinical Evaluation Reports and Trial Alternatives in China
A guide to navigating China's stringent NMPA clinical requirements, focusing on the Clinical Trial Exemption List, the use of Clinical Evaluation Reports (CERs) as a core submission, and the alternatives to performing costly local clinical trials (e.g., predicate device comparison).
Approximately 5 minutes
NMPA Regulation of Stand-Alone Medical Software (SaMD): AI, Cloud, and Data Requirements
An overview of China's regulatory framework for Stand-Alone Medical Software (SaMD), covering classification (Class II/III), specific requirements for AI and Cloud storage (must use a Chinese provider), and the need to establish compliant local patient databases.
Approximately 5 minutes
China's National Medical Products Administration (NMPA): Regulatory Body and Recent Reforms
The NMPA is China's national regulatory body for medical devices, IVDs, and drugs. Since changing its name from CFDA in 2018, the NMPA has focused on international alignment, improving review transparency (e.g., Clinical Trial Exemption Lists), and streamlining processes.
Approximately 5 minutes
Navigating China NMPA Medical Device Registration: An Expert Interview with Peter of Ecomajor
An expert guide to China's NMPA medical device regulations for 2026. Peter from Ecomajor explains offline filing for Class 1, ERPS submissions for Class 2 and 3, fee structures, and how to mitigate distributor hostage risks.
Approximately 5 minutes
Eight Asian Markets, One Regulatory Map: A Medical Device Market-Access Field Guide
A systematic, jurisdiction-by-jurisdiction review of medical device regulation across China, India, Singapore, Malaysia, Indonesia, Bangladesh, and Kazakhstan, closing with a cross-cutting comparison of classification, digitalization, local-agent risk, timelines, and the universal value of CE marking and ISO 13485.